MedTrace Logo

An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis

NCT00739739 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 161

Last updated 2011-03-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether PD 0299685 is effective in the treatment of symptoms associated with interstitial cystitis/painful bladder syndrome, such as pain, urinary urgency and frequency. At the same time assess the drug's safety and tolerability.

Conditions

  • Interstitial Cystitis
  • Painful Bladder Syndrome

Interventions

DRUG

PD 0299685 at 15mg BID

5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study

DRUG

PD 0299685 at 30mg BID

10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.

DRUG

placebo for PD 0299685

Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States
  • Canada
  • Denmark
  • Finland
  • France
  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00739739 on ClinicalTrials.gov